GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery

Condition(s) studied

Investigational drug(s) / intervention(s)

Dulaglutide 0.75mg subcutaneous injection: Subject randomized into treatment group will receive single subcutaneous dose of Dulaglutide 0.75mg 1 to 14 days prior to surgery

Study summary

This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery. Recruited patients will be randomized in a 2:1 ratio to receive single subcutaneous dose of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RAs) 1 to 14 days prior to surgery or receive routine care.

Dulaglutide (Trulicity; Eli Lilly, USA) is chosen as GLP-1 Receptor Agonists investigational drug for this study. Apart from peri-operative routine care, all recruited subjects will undergo physical, respiratory and cardiac assessments including electrocardiography and blood check including cardiac enzymes. Myocardial injury, cardiovascular outcomes and safety will be assessed and evaluated for efficacy and safety of this prophylactic measurement for the reduction of myocardial injury after non-cardiac surgery.

Eligibility

Primary outcome measure(s)

• Proportion of patients with MINS — Within 72 hours after surgery
  Defined as any elevation in troponin T \>= 14ng/L

Trial sites (3)

More The University of Hong Kong trials in China

Other trials for the same condition